GE and Geron to work on embryonic stem cell assays
This article was originally published in Clinica
Executive Summary
GE Healthcare is to partner with pharmaceutical firm Geron in the development of cellular assays for use in drug discovery, drug development and toxicity screening. As part of an exclusive global alliance, scientists from the two companies will work on assay products derived from human embryonic stem cells (hESCs). GE will fund the research and development process for the assays, and will also be responsible for the manufacturing, sales and distribution of the resulting products. Financial terms of the deal were not disclosed. According to GE, the partnership with Geron is designed to improve early in vitro screening of drug candidates and, in turn, reduce both overall drug development costs and potentially harmful patient exposure during clinical trials.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals